CHU Grenoble Alpes

The CHU Grenoble Alpes pediatric oncology unit is conducting research on acute lymphoblastic leukemia in children and adolescents, testing new dosing schedules of pegaspargase to improve drug exposure and reduce side effects.

• Optimizing induction therapy for standard‑risk ALL
• Assessing fractionated pegaspargase regimens
• Evaluating toxicity profiles in medium‑risk pediatric patients

With 177 investigators participating, the study aims to enhance survival rates and quality of life for young patients while providing valuable data on pharmacokinetics and tolerance.

Researchers at CHU Grenoble Alpes are evaluating the combination of olomorasib with immune checkpoint inhibitors for KRAS G12C‑mutant non‑small cell lung cancer, seeking to boost treatment efficacy and monitor safety in patients with unresectable disease.

• Targeted KRAS inhibition strategies
• Combination with PD‑1/PD‑L1 blockade
• Biomarker‑driven patient stratification

This multicenter, open‑label trial integrates detailed immunophenotypic profiling to identify which patients benefit most, aiming to expand therapeutic options for a challenging cancer subtype.